Tarsus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $118,697 | $102,660 | $78,335 | $66,408 |
Gross Profit | 94,104 | 96,423 | 73,124 | 61,482 |
EBITDA | -12,125 | -17,647 | -22,447 | -20,369 |
EBIT | -12,585 | -18,100 | -22,907 | -20,801 |
Net Income | -12,585 | -20,340 | -25,120 | -23,113 |
Net Change In Cash | 118,697 | 102,660 | 78,335 | 66,408 |
Free Cash Flow | 16,347 | -30,388 | -21,241 | -27,254 |
Cash | 112,724 | 96,648 | 175,787 | 94,819 |
Basic Shares | 42,607 | 42,360 | 39,345 | 38,560 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $182,953 | $17,447 | $25,816 | $57,027 |
Gross Profit | 170,127 | 15,854 | 24,861 | 54,952 |
EBITDA | -106,480 | -131,670 | -59,705 | -13,460 |
EBIT | -107,705 | -132,547 | -60,031 | -13,772 |
Net Income | -115,554 | -135,893 | -62,091 | -13,827 |
Net Change In Cash | 182,953 | 17,447 | 25,816 | 57,027 |
Cost of Revenue | -99,672 | 3,183 | ||
Free Cash Flow | -84,594 | -122,995 | -49,536 | 3,162 |
Cash | 94,819 | 224,947 | 71,660 | 171,332 |
Basic Shares | 37,604 | 29,383 | 24,619 | 20,554 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.30 |
2025-06-30 | -$0.48 |
2025-03-31 | -$0.64 |
2024-12-31 | -$0.60 |
